Compare Adaptive Biotechnologies Corp (ADPT) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JPMorgan Ultra Short Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while JPMorgan Ultra Short Income ETF trades at $50.46. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | JPST | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $25.45 | $50.78 |
52-Week Low | $12.30 | $50.40 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPST (JPMorgan Ultra-Short Income ETF) trades at $50.44, showing minimal daily movement with a 0.08% gain. The technical picture remains bearish with moving averages signaling caution, though the RSI suggests potential oversold conditions. Recent institutional activity shows growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund maintains consistent dividend distributions of $0.17 per share, providing stable income for risk-averse investors seeking short-term bond exposure.
As an ultra-short income ETF, JPST offers conservative investors a cash-alternative with slightly higher yields than T-bills. The fund's stability and consistent dividends make it attractive for parking cash between investments or during uncertain rate environments. However, rising interest rates and inflation pressures pose headwinds for short-term bond performance. The ETF's bearish technical signals warrant monitoring, though its defensive positioning provides downside protection in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
